[Pneumococcus and quinolone resistance].
Bello
S
S
Torres
A
A
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001372:Aza Compounds; D002675:Child, Preschool; D002939:Ciprofloxacin / Q000494:pharmacology / Q000627:therapeutic use; D004269:DNA, Bacterial; D024881:Drug Resistance, Bacterial; D024841:Fluoroquinolones; D000077734:Gatifloxacin; D005798:Genes, Bacterial; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D015999:Multivariate Analysis; D009154:Mutation; D015242:Ofloxacin / Q000494:pharmacology / Q000627:therapeutic use; D010403:Penicillin Resistance; D010406:Penicillins / Q000494:pharmacology; D011008:Pneumococcal Infections / Q000188:drug therapy*; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy; D011804:Quinolines; D012008:Recurrence; D012307:Risk Factors; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D001372:Aza Compounds; D004269:DNA, Bacterial; D024841:Fluoroquinolones; D010406:Penicillins; D011804:Quinolines; D002939:Ciprofloxacin; D015242:Ofloxacin; D000077734:Gatifloxacin; D000077266:Moxifloxacin